CHNA vs NHF

Loncar China BioPharma ETF

The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). Under normal circumstances, at least 80% of the fund's total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the index or in depositary receipts representing such component securities. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries. The fund is non-diversified.

NexPoint Strategic Opportunities Fund

NexPoint Strategic Opportunities Fund is a closed ended balanced mutual fund launched by Highland Capital Management, L.P. It is managed by Nexpoint Advisors, L.P. The fund invests in the fixed income markets of the United States. It invests in companies across broadly diversified sectors to construct its portfolio. The fund typically invests in senior loans, secured and unsecured floating and fixed rate loans, bonds, debt obligations of stressed, distressed, and bankrupt issuers, mortgage-backed securities, asset-backed securities, and collateralized debt obligations with a primary focus on below investment grade debt and equity securities. It employs a quantitative analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the Dow Jones Credit Suisse Hedge Fund and the HFRX Global Hedge Fund. It was formerly known as NexPoint Credit Strategies Fund. NexPoint Strategic Opportunities Fund was formed on June 1, 2006 and is domiciled in the United States.